Key result
Adenovirus infections in heart transplant recipients are associated with an increased risk of adverse cardiac events, including rejection, ventricular dysfunction, and graft loss.
Adenovirus infections in heart transplant recipients are associated with significant adverse cardiac events, and cidofovir is considered the standard treatment for cases unresponsive to immunosuppression reduction.
Answers are grounded in this paper and cite their sources.
Supports vigilant monitoring for adenovirus post-transplant; leaves open whether antivirals alter graft outcomes.
Adenovirus infections have been associated with significant morbidity and mortality in immunocompromised hosts. The clinical significance of adenovirus disease in heart transplantation is not well-defined; in particular, the significance of adenovirus identification in myocardium remains unclear. Although severe adenovirus disease has been described in heart transplant recipients, adenovirus infections seem to be more frequently associated with increased risk of adverse cardiac events, such as rejection, ventricular dysfunction, coronary vasculopathy, need for retransplantation, and graft loss because of death. Cidofovir is currently considered the standard of treatment for adenovirus disease not responding to reduction of immunosuppression.
No takes yet. Share an insight, caveat, or question.
Florescu et al. (2013) conducted a review in Adenovirus infections in heart transplantation. Adenovirus infections was evaluated. Adenovirus infections in heart transplant recipients are associated with an increased risk of adverse cardiac events, including rejection, ventricular dysfunction, and graft loss.
Synapse has enriched 10 related papers. Consider them for comparative context: